Hyperimmune goat serum (Aimspro®): Hope or hype?
Sutton, I. and Kermode, A.G. (2006) Hyperimmune goat serum (Aimspro®): Hope or hype? Journal of Clinical Neuroscience, 13 (10). pp. 1037-1038.
*Subscription may be required
In March 2005, newspaper and television reports from the UK suggested that treatment with Aimspro®, a ‘hyperimmune goat serum’ (HGS), resulted in an improvement in symptoms attributed to multiple sclerosis. In September 2005, the Hansard record of UK parliamentary debates noted while at least 250 people with multiple sclerosis had received this product, it was unlicensed and a report by the UK Medicines and Healthcare Regulatory Agency (MHRA), had found ‘critical and major deficiencies concerning good manufacturing practice’. Furthermore, the MHRA had previously requested that product manufacturers, Daval International Ltd, remove misleading claims regarding HGS from its website: to date there is no data regarding mechanism of action or demonstration of clinical efficacy in a placebo-controlled trial that has been published in a peer-reviewed full-length journal article...
|Publication Type:||Journal Article|
|Copyright:||© 2006 Elsevier Ltd.|
|Item Control Page|